Drug Profile
ZD 9255
Latest Information Update: 07 Apr 1999
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Anti-ischaemics; Neuroprotectants; Vascular disorder therapies; Vasodilators
- Mechanism of Action Purinergic P1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cerebrovascular disorders; Intermittent claudication; Ischaemic heart disorders; Peripheral vascular disorders
Most Recent Events
- 07 Apr 1999 Merger of Zeneca and Astra to form AstraZeneca completed
- 18 Jan 1996 Discontinued-Preclinical for Cerebrovascular disorders in United Kingdom (Unknown route)
- 18 Jan 1996 Discontinued-Preclinical for Intermittent claudication in United Kingdom (Unknown route)